Artur / iStockphoto.com
Late last week, Chugai Pharmaceutical emerged victorious after the English High Court found that the Japan-based company doesn’t owe royalties under a patent licence with UCB.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
English High Court, UCB Pharma, Chugai, patent, Celltech, licence, royalties, antibodies, tocilizumab